BALTIMORE —

Maryland is helping improve access to life-saving sickle cell treatments.

The state joined the federal Cell and Gene Therapy Access Model , which specifically benefits sickle cell patients on Medicaid. Latest Forecast

° F FEELS LIKE No weather data available

HOURLY

DAILY RADAR TRAFFIC

Under the model, the Centers for Medicare and Medicaid Services will negotiate rebate agreements with pharmaceutical manufacturers that will save Maryland about $1 million per patient.

So, what does this mean for patients?

Medicaid participants can already access cell and gene therapies through standard coverage, but starting on Jan. 1, 2026, Maryland will receive rebates and financial protections. The hope is this will help bring down the costs of the therapies for patients

See Full Page